Anti-Human BCMA/TNFRSF17 Reference Antibody (PRG1801, RUO) (HX959156)

Name: Anti-Human BCMA/TNFRSF17 Reference Antibody (PRG1801, RUO)
Brand: abinScience
SKU: HX959156
Price: 370 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HX959156
Description	Anti-Human CD269/TNFRSF17/BCMA (PRG1801) (HX959156) is a research-grade recombinant antibody targeting CD269. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG
ID de clone	PRG1801
Cible	B-cell maturation protein, BCM, BCMA, CD269, TNFRSF17, Tumor necrosis factor receptor superfamily member 17
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	Q02223
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	PRG1801
Contexte	Tumor necrosis factor receptor superfamily member 17 (CD269/BCMA) is a ~20 kDa protein. Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. CD269 is the therapeutic target of teclistamab (Tecvayli).
Note	For research use only. Not suitable for clinical or therapeutic use.